Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir and rilpivirine suggest potential compatibility and effectiveness as a two-drug regimen. We aimed to investigate this two-drug regimen in a phase 3 study.

中文翻译：

---

dolutegravir-rilpivirine维持HIV-1成人病毒抑制的功效，安全性和耐受性：3期，随机，非劣效性SWORD-1和SWORD-2研究。

终生的HIV抗逆转录病毒疗法（ART）促使人们对两种药物疗法产生了兴趣，以最大程度地减少累积药物暴露和毒性。Dolutegravir和rilpivirine的安全性，耐受性和功效表明，作为两种药物的治疗方案具有潜在的相容性和有效性。我们旨在在3期研究中研究这种两种药物的治疗方案。